{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:53:57Z","timestamp":1794048837173,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University received financial support from Pfizer for this study."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Community-acquired pneumonia (CAP) substantially contributes to mortality and morbidity globally, with beta-lactams being a primary therapeutic agent. The efficacy of adding macrolides to beta-lactams in CAP treatment remains controversial. Here, we evaluated whether beta-lactam plus macrolide treatment (BLM) is more effective than beta-lactam monotherapy (BL) for preventing CAP mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a secondary data analysis of a multicenter prospective cohort study involving patients diagnosed with CAP at four institutions. We selected patients treated with either BLM or BL. The primary endpoint was the outcome at the end of the observation period (death or recovery). The secondary endpoints were the length of hospital stay and duration of antibiotic use. Multiple imputations with bootstrapping were used to address missing data. Background characteristics were adjusted via propensity score matching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 3,470 patients initially included in the study, 2,784 were analyzed; 306 received BLM and 2,478 received BL. The average observation period for the groups was 17.0 (\u00b1\u200918.4) and 24.0 days (\u00b1\u200924.6), respectively. After propensity score matching, mortality was similar between the groups (5.06% for BLM vs. 4.98% for BL; difference 0.00, 95% confidence interval [CI]\u2009\u2212\u20093.73 to 3.71), as were recovery rates (91.79% for BLM vs. 91.69% for BL; difference 0.00, 95% CI \u2212\u20094.48 to 4.82). In the subgroup analysis of patients with severe CAP, mortality was 12.00% for BLM vs. 13.33% for BL (difference 0.00, 95% CI \u2212\u200920.00 to 16.13), and recovery rates were 82.86% vs. 83.33% (difference 0.00, 95% CI \u2212\u200920.00 to 20.00).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Similar outcomes were observed in the mortality and recovery rates between the BLM and BL groups among patients with CAP. Clinicians should thoughtfully weigh the benefits of BLM against the potential risks, including adverse effects and antimicrobial resistance, when managing patients with CAP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This study protocol was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR), identifier UMIN000006909, on December 19, 2011.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12408-x","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T03:54:44Z","timestamp":1766980484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beta-lactam plus macrolide treatment versus beta-lactam monotherapy for community-acquired pneumonia: a propensity score analysis using data from a multicenter prospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Kei","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Aoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konosuke","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koya","family":"Ariyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Adult Pneumonia Study Group \u2013 Japan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"12408_CR1","unstructured":"World Health Organization. Fact sheets, The top 10 causes of death. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death [Accessed 27 Apr 2024]."},{"issue":"6","key":"12408_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jama.2013.333","volume":"309","author":"HM Krumholz","year":"2013","unstructured":"Krumholz HM, Lin Z, Keenan PS, Chen J, Ross JS, Drye EE, Bernheim SM, Wang Y, Bradley EH, Han LF, et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial Infarction, heart Failure, or pneumonia. JAMA. 2013;309(6):587.","journal-title":"JAMA"},{"issue":"7","key":"12408_CR3","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, et al. Diagnosis and treatment of adults with Community-acquired Pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367.","journal-title":"Am J Respir Crit Care Med"},{"key":"12408_CR4","unstructured":"National Institute for Health and Care Excellence. Pneumonia (community-acquired): antimicrobial prescribing. NICE guideline [NG138] Published: 16 September 2019. Available: https:\/\/www.nice.org.uk\/guidance\/ng138\/chapter\/Recommendations [Accessed 27 Apr 2024]."},{"issue":"7","key":"12408_CR5","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/resp.12835","volume":"21","author":"N Horita","year":"2016","unstructured":"Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, Higa F, Takahashi H, Yoshida M, Kohno S, et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis. Respirology. 2016;21(7):1193\u2013200.","journal-title":"Respirology"},{"issue":"1","key":"12408_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.idc.2012.11.005","volume":"27","author":"TM File Jr","year":"2013","unstructured":"File TM Jr., Marrie TJ. Does empiric therapy for atypical pathogens improve outcomes for patients with CAP? Infect Dis Clin North Am. 2013;27(1):99\u2013114.","journal-title":"Infect Dis Clin North Am"},{"issue":"5","key":"12408_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/thoraxjnl-2012-202296","volume":"68","author":"C Rodrigo","year":"2013","unstructured":"Rodrigo C, McKeever TM, Woodhead M, Lim WS, British Thoracic S. Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax. 2013;68(5):493\u20135.","journal-title":"Thorax"},{"issue":"Suppl 3","key":"12408_CR8","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1086\/591404","volume":"47","author":"DW Bratzler","year":"2008","unstructured":"Bratzler DW, Ma A, Nsa W. Initial antibiotic selection and patient outcomes: observations from the National pneumonia project. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2008;47(Suppl 3):S193\u2013201.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"4","key":"12408_CR9","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1183\/09031936.00092607","volume":"32","author":"F Blasi","year":"2008","unstructured":"Blasi F, Iori I, Bulfoni A, Corrao S, Costantino S, Legnani D. Can CAP guideline adherence improve patient outcome in internal medicine departments? Eur Respir J. 2008;32(4):902\u201310.","journal-title":"Eur Respir J"},{"issue":"4","key":"12408_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S2213-2600(23)00412-5","volume":"12","author":"EJ Giamarellos-Bourboulis","year":"2024","unstructured":"Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, Doulou S, Kakavoulis N, Tsiakos K, Katopodis S, Schinas G, Skorda L, Alexiou Z, et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2024;12(4):294\u2013304.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"12408_CR11","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","volume":"174","author":"N Garin","year":"2014","unstructured":"Garin N, Genne D, Carballo S, Chuard C, Eich G, Hugli O, Lamy O, Nendaz M, Petignat PA, Perneger T, et al. beta-Lactam monotherapy vs beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174(12):1894\u2013901.","journal-title":"JAMA Intern Med"},{"issue":"14","key":"12408_CR12","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","volume":"372","author":"DF Postma","year":"2015","unstructured":"Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372(14):1312\u201323.","journal-title":"N Engl J Med"},{"key":"12408_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jgar.2022.05.009","volume":"30","author":"LY Xu","year":"2022","unstructured":"Xu LY, Wang CC, Peng XX, Jiao Y, Zhao CZ, Zhang L, Ma L. Empirical antibiotic treatment strategies for community-acquired pneumonia: a network meta-analysis. J Glob Antimicrob Resist. 2022;30:1\u20139.","journal-title":"J Glob Antimicrob Resist"},{"issue":"4","key":"12408_CR14","doi-asserted-by":"publisher","first-page":"e713","DOI":"10.1093\/infdis\/jiae639","volume":"231","author":"J Wei","year":"2025","unstructured":"Wei J, Walker AS, Eyre DW. Addition of macrolide antibiotics for hospital treatment of Community-Acquired pneumonia. J Infect Dis. 2025;231(4):e713\u201322.","journal-title":"J Infect Dis"},{"key":"12408_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jclinepi.2021.08.028","volume":"144","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n MA. Causal analyses of existing databases: no power calculations required. J Clin Epidemiol. 2022;144:203\u20135.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"12408_CR16","doi-asserted-by":"publisher","first-page":"e0122247","DOI":"10.1371\/journal.pone.0122247","volume":"10","author":"K Morimoto","year":"2015","unstructured":"Morimoto K, Suzuki M, Ishifuji T, Yaegashi M, Asoh N, Hamashige N, Abe M, Aoshima M, Ariyoshi K. Adult pneumonia study G-J: the burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLoS ONE. 2015;10(3):e0122247.","journal-title":"PLoS ONE"},{"key":"12408_CR17","unstructured":"The Sanford Guide to Antimicrobial Therapy. Available form: https:\/\/web.sanfordguide.com\/. Accessed: April 7, 2025."},{"issue":"1","key":"12408_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/INF.0b013e3181af61e9","volume":"29","author":"LM Yoshida","year":"2010","unstructured":"Yoshida LM, Suzuki M, Yamamoto T, Nguyen HA, Nguyen CD, Nguyen AT, Oishi K, Vu TD, Le TH, Le MQ, et al. Viral pathogens associated with acute respiratory infections in central Vietnamese children. Pediatr Infect Dis J. 2010;29(1):75\u20137.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"12408_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/INF.0b013e3181f111a2","volume":"30","author":"HT Vu","year":"2011","unstructured":"Vu HT, Yoshida LM, Suzuki M, Nguyen HA, Nguyen CD, Nguyen AT, Oishi K, Yamamoto T, Watanabe K, Vu TD. Association between nasopharyngeal load of Streptococcus pneumoniae, viral coinfection, and radiologically confirmed pneumonia in Vietnamese children. Pediatr Infect Dis J. 2011;30(1):11\u20138.","journal-title":"Pediatr Infect Dis J"},{"key":"12408_CR20","unstructured":"tableone. Create \u2018Table 1\u2019 to Describe Baseline Characteristics with or without Propensity Score Weights. Available: https:\/\/cran.r-project.org\/web\/packages\/tableone\/index.html [Accessed 27 Apr 2024]."},{"issue":"3","key":"12408_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1\u201367.","journal-title":"J Stat Softw"},{"issue":"3","key":"12408_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/pan\/mpl013","volume":"15","author":"DE Ho","year":"2007","unstructured":"Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political Anal. 2007;15(3):199\u2013236.","journal-title":"Political Anal"},{"issue":"3","key":"12408_CR23","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ. A class of $K$-Sample tests for comparing the cumulative incidence of a competing risk. Annals Stat. 1988;16(3):1141\u201354.","journal-title":"Annals Stat"},{"issue":"446","key":"12408_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509.","journal-title":"J Am Stat Assoc"},{"issue":"14","key":"12408_CR25","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/sim.7654","volume":"37","author":"M Schomaker","year":"2018","unstructured":"Schomaker M, Heumann C. Bootstrap inference when using multiple imputation. Stat Med. 2018;37(14):2252\u201366.","journal-title":"Stat Med"},{"issue":"4","key":"12408_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJM199701233360402","volume":"336","author":"MJ Fine","year":"1997","unstructured":"Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify Low-Risk patients with Community-Acquired pneumonia. N Engl J Med. 1997;336(4):243\u201350.","journal-title":"N Engl J Med"},{"issue":"7","key":"12408_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1056\/NEJMra1714562","volume":"380","author":"LA Mandell","year":"2019","unstructured":"Mandell LA, Niederman MS. Aspiration pneumonia. N Engl J Med. 2019;380(7):651\u201363.","journal-title":"N Engl J Med"},{"issue":"3","key":"12408_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1086\/589754","volume":"47","author":"PG Charles","year":"2008","unstructured":"Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2008;47(3):375\u201384.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"25","key":"12408_CR29","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"issue":"5","key":"12408_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/thorax.58.5.377","volume":"58","author":"WS Lim","year":"2003","unstructured":"Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377\u201382.","journal-title":"Thorax"},{"key":"12408_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.rmed.2018.05.020","volume":"140","author":"FW Arnold","year":"2018","unstructured":"Arnold FW, Lopardo G, Wiemken TL, Kelley R, Peyrani P, Mattingly WA, Feldman C, Gnoni M, Maurici R, Ramirez JA, et al. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. Respir Med. 2018;140:115\u201321.","journal-title":"Respir Med"},{"issue":"4","key":"12408_CR32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.chest.2018.11.006","volume":"155","author":"A Ceccato","year":"2019","unstructured":"Ceccato A, Cilloniz C, Martin-Loeches I, Ranzani OT, Gabarrus A, Bueno L, Garcia-Vidal C, Ferrer M, Niederman MS, Torres A. Effect of combined beta-Lactam\/Macrolide therapy on mortality according to the microbial etiology and inflammatory status of patients with Community-Acquired pneumonia. Chest. 2019;155(4):795\u2013804.","journal-title":"Chest"},{"issue":"1","key":"12408_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1183\/09031936.00054108","volume":"33","author":"MI Restrepo","year":"2009","unstructured":"Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;33(1):153\u20139.","journal-title":"Eur Respir J"},{"issue":"9","key":"12408_CR34","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1513\/AnnalsATS.201906-459OC","volume":"18","author":"E Sando","year":"2021","unstructured":"Sando E, Suzuki M, Ishida M, Yaegashi M, Aoshima M, Ariyoshi K, Morimoto K. Definitive and indeterminate Pseudomonas aeruginosa infection in adults with Community-acquired pneumonia: A prospective observational study. Annals Am Thorac Soc. 2021;18(9):1475\u201381.","journal-title":"Annals Am Thorac Soc"},{"key":"12408_CR35","unstructured":"The Japanese Respiratory Society (JRS). The JRS Guideline for the Management of Pneumonia in Adults 2024. Available: https:\/\/www.jrs.or.jp\/publication\/jrs_guidelines\/20240319125656.html [Accessed 27 Apr 2024]."},{"issue":"20","key":"12408_CR36","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","volume":"366","author":"WA Ray","year":"2012","unstructured":"Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881\u201390.","journal-title":"N Engl J Med"},{"issue":"21","key":"12408_CR37","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1001\/jama.2014.4304","volume":"311","author":"EM Mortensen","year":"2014","unstructured":"Mortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ, Johnson CS, Alvarez CA, Frei CR, Good C, et al. Association of Azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA. 2014;311(21):2199.","journal-title":"JAMA"},{"key":"12408_CR38","doi-asserted-by":"crossref","unstructured":"Konig R, Cao X, Oswald M, Forstner C, Rohde G, Rupp J, Witzenrath M, Welte T, Kolditz M, Pletz M, et al. Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning. Eur Respir J. 2019;54(6).","DOI":"10.1183\/13993003.00824-2019"},{"issue":"3","key":"12408_CR39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1128\/CMR.00058-15","volume":"29","author":"L Kim","year":"2016","unstructured":"Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate vaccine eras: a united States perspective. Clin Microbiol Rev. 2016;29(3):525\u201352.","journal-title":"Clin Microbiol Rev"},{"key":"12408_CR40","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2147\/IJGM.S145133","volume":"10","author":"W Wanla","year":"2017","unstructured":"Wanla W, Katip W, Supakul S, Apiwatnakorn P, Khamsarn S. Effects of an antimicrobial restriction system on appropriate carbapenem use in a hospital without infectious diseases consultation. Int J Gen Med. 2017;10:443\u20139.","journal-title":"Int J Gen Med"},{"issue":"5","key":"12408_CR41","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/jac\/dkp088","volume":"63","author":"A Tessmer","year":"2009","unstructured":"Tessmer A, Welte T, Martus P, Schnoor M, Marre R, Suttorp N. Impact of intravenous {beta}-lactam\/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother. 2009;63(5):1025\u201333.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"12408_CR42","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","volume":"36","author":"I Martin-Loeches","year":"2010","unstructured":"Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, Restrepo MI, Rello J. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010;36(4):612\u201320.","journal-title":"Intensive Care Med"},{"key":"12408_CR43","doi-asserted-by":"crossref","unstructured":"Eliakim-Raz N, Robenshtok E, Shefet D, Gafter-Gvili A, Vidal L, Paul M, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Reviews. 2012.","DOI":"10.1002\/14651858.CD004418.pub4"},{"issue":"5","key":"12408_CR44","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1099\/jmm.0.000479","volume":"66","author":"M Kawaguchiya","year":"2017","unstructured":"Kawaguchiya M, Urushibara N, Aung MS, Shinagawa M, Takahashi S, Kobayashi N. Serotype distribution, antimicrobial resistance and prevalence of Pilus Islets in Pneumococci following the use of conjugate vaccines. J Med Microbiol. 2017;66(5):643\u201350.","journal-title":"J Med Microbiol"},{"issue":"15","key":"12408_CR45","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.2169\/internalmedicine.53.1418","volume":"53","author":"S Hanada","year":"2014","unstructured":"Hanada S, Morozumi M, Takahashi Y, Mochizuki S, Sato T, Suzuki S, Uruga H, Takaya H, Miyamoto A, Morokawa N, et al. Community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae in adults. Intern Med. 2014;53(15):1675\u20138.","journal-title":"Intern Med"},{"issue":"10","key":"12408_CR46","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3201\/eid2310.170106","volume":"23","author":"T Tanaka","year":"2017","unstructured":"Tanaka T, Oishi T, Miyata I, Wakabayashi S, Kono M, Ono S, Kato A, Fukuda Y, Saito A, Kondo E, et al. Macrolide-Resistant Mycoplasma pneumoniae Infection, Japan, 2008\u20132015. Emerg Infect Dis. 2017;23(10):1703\u20136.","journal-title":"Emerg Infect Dis"},{"key":"12408_CR47","doi-asserted-by":"publisher","first-page":"1391879","DOI":"10.3389\/fcimb.2024.1391879","volume":"14","author":"T Nakao","year":"2024","unstructured":"Nakao T, Kosai K, Akamatsu N, Ota K, Mitsumoto-Kaseida F, Hasegawa H, Izumikawa K, Mukae H, Yanagihara K. Molecular and phenotypic characterization of Streptococcus pneumoniae isolates in a Japanese tertiary care hospital. Front Cell Infect Microbiol. 2024;14:1391879.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"12408_CR48","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.resinv.2025.04.009","volume":"63","author":"N Miyashita","year":"2025","unstructured":"Miyashita N, Ogata M, Fukuda N, Yamura A, Ito T. Macrolide-resistant Mycoplasma pneumoniae infection prevalence increases again in Osaka. Respir Investig. 2025;63(4):517\u201320.","journal-title":"Respir Investig"},{"issue":"2","key":"12408_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S1473-3099(21)00255-3","volume":"22","author":"VA Schweitzer","year":"2022","unstructured":"Schweitzer VA, van Heijl I, Boersma WG, Rozemeijer W, Verduin K, Grootenboers MJ, Sankatsing SUC, van der Bij AK, de Bruijn W, Ammerlaan HSM, et al. Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial. Lancet Infect Dis. 2022;22(2):274\u201383.","journal-title":"Lancet Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12408-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12408-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12408-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:53:25Z","timestamp":1781625205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12408-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12408"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12408-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5738269\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the ethics review boards of the Institute of Tropical Medicine at Nagasaki University, Ebetsu City Hospital, Kameda Medical Center, Chikamori Hospital, and Juzenkai Hospital (registration no. 11063070). This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. We obtained written informed consent from all conscious patients. In the cases of adults with cognitive decline, a legal guardian or an appropriate representative of these participants provided informed consent on their behalf. Given that the study was observational and involved no invasive interventions or deviations from standard medical treatment, all the institutional review boards waived the requirement for written informed consent for a few unconscious patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K.M. received research funding support from Pfizer. K.M. and K.A. received collaborative research funding from Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"216"}}